Merck has decided to return to Scynexis all development and commercialization rights for the novel antifungal compound MK-3118, an oral glucan synthase inhibitor being developed for the treatment of systemic fungal diseases. This decision was made following a review and prioritization of Merck’s infectious disease portfolio. In 2002, Scynexis and Merck announced an exclusive license and research agreement focused on antifungal discovery and development of treatments for invasive fungal in...